Literature DB >> 32317112

Gut microbiota generation of protein-bound uremic toxins and related metabolites is not altered at different stages of chronic kidney disease.

Tessa Gryp1, Kim De Paepe2, Raymond Vanholder3, Frederiek-Maarten Kerckhof2, Wim Van Biesen3, Tom Van de Wiele2, Francis Verbeke3, Marijn Speeckaert3, Marie Joossens4, Marie Madeleine Couttenye5, Mario Vaneechoutte6, Griet Glorieux3.   

Abstract

Chronic kidney disease (CKD) is characterized by accumulation of protein-bound uremic toxins such as p-cresyl sulfate, p-cresyl glucuronide, indoxyl sulfate and indole-3-acetic acid, which originate in the gut. Intestinal bacteria metabolize aromatic amino acids into p-cresol and indole, (further conjugated in the colon mucosa and liver) and indole-3-acetic acid. Here we measured fecal, plasma and urine metabolite concentrations; the contribution of gut bacterial generation to plasma protein-bound uremic toxins accumulation; and influx into the gut of circulating protein-bound uremic toxins at different stages of CKD. Feces, blood and urine were collected from 14 control individuals and 141 patients with CKD. Solutes were quantified by ultra-high performance liquid chromatography. To assess the rate of bacterial generation of p-cresol, indole and indole-3-acetic acid, fecal samples were cultured ex vivo. With CKD progression, an increase in protein-bound uremic toxins levels was observed in plasma, whereas the levels of these toxins and their precursors remained the same in feces and urine. Anaerobic culture of fecal samples showed no difference in ex vivo p-cresol, indole and indole-3-acetic acid generation. Therefore, differences in plasma protein-bound uremic toxins levels between different CKD stages cannot be explained by differences in bacterial generation rates in the gut, suggesting retention due to impaired kidney function as the main contributor to their increased plasma levels. Thus, as fractional clearance decreased with the progression of CKD, tubular clearance appeared to be more affected than the glomerular filtration rate, and there was no net increase in protein-bound uremic toxins influx into the gut lumen with increased plasma levels.
Copyright © 2020 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  bacterial metabolization; chronic kidney disease; feces; plasma; protein-bound uremic toxins; urine

Mesh:

Substances:

Year:  2020        PMID: 32317112     DOI: 10.1016/j.kint.2020.01.028

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  36 in total

1.  Microbial metabolism of L-tyrosine protects against allergic airway inflammation.

Authors:  Tomasz P Wypych; Céline Pattaroni; Olaf Perdijk; Carmen Yap; Aurélien Trompette; Dovile Anderson; Darren J Creek; Nicola L Harris; Benjamin J Marsland
Journal:  Nat Immunol       Date:  2021-01-25       Impact factor: 25.606

Review 2.  Effects of the L-tyrosine-derived bacterial metabolite p-cresol on colonic and peripheral cells.

Authors:  F Blachier; M Andriamihaja
Journal:  Amino Acids       Date:  2021-09-01       Impact factor: 3.520

3.  Serum concentrations of free indoxyl and p-cresyl sulfate are associated with mineral metabolism variables and cardiovascular risk in hemodialysis patients.

Authors:  Teresa Arcidiacono; Lorenza Macrina; Simone Premaschi; Arianna Bologna; Giulia Magni; Nadia Foligno; Monica Avino; Cristina Belloni; Nicola Palmieri; Ferruccio Conte; Sergio Bisegna; Marco Simonini; Giorgio Slaviero; Massimo Locatelli; Giuseppe Vezzoli
Journal:  J Nephrol       Date:  2022-02-17       Impact factor: 4.393

4.  Indole-3-acetic acid correlates with monocyte-to-high-density lipoprotein (HDL) ratio (MHR) in chronic kidney disease patients.

Authors:  Valeria Cernaro; Vincenzo Calabrese; Saverio Loddo; Roberta Corsaro; Vincenzo Macaione; Valentina Teresa Ferlazzo; Rosalia Maria Cigala; Francesco Crea; Concetta De Stefano; Guido Gembillo; Adolfo Romeo; Elisa Longhitano; Domenico Santoro; Michele Buemi; Salvatore Benvenga
Journal:  Int Urol Nephrol       Date:  2022-02-11       Impact factor: 2.266

5.  Effects of Microbiota-Driven Therapy on Circulating Indoxyl Sulfate and P-Cresyl Sulfate in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Li Chen; Junhe Shi; Xiaojuan Ma; Dazhuo Shi; Hua Qu
Journal:  Adv Nutr       Date:  2022-08-01       Impact factor: 11.567

Review 6.  Uraemic solutes as therapeutic targets in CKD-associated cardiovascular disease.

Authors:  Jonathan D Ravid; Mohamed Hassan Kamel; Vipul C Chitalia
Journal:  Nat Rev Nephrol       Date:  2021-03-23       Impact factor: 28.314

7.  Dual effects of the tryptophan-derived bacterial metabolite indole on colonic epithelial cell metabolism and physiology: comparison with its co-metabolite indoxyl sulfate.

Authors:  Lucie Armand; Masou Fofana; Kristell Couturier-Becavin; Mireille Andriamihaja; François Blachier
Journal:  Amino Acids       Date:  2022-02-02       Impact factor: 3.520

8.  Kidney Tubulointerstitial Fibrosis and Tubular Secretion.

Authors:  Pranav S Garimella; Ronit Katz; Sushrut S Waikar; Anand Srivastava; Insa Schmidt; Andrew Hoofnagle; Ragnar Palsson; Helmut G Rennke; Isaac E Stillman; Ke Wang; Bryan R Kestenbaum; Joachim H Ix
Journal:  Am J Kidney Dis       Date:  2021-09-24       Impact factor: 11.072

9.  High-Sensitivity Troponin for Suspected Acute Coronary Syndrome in Patients With Chronic Kidney Disease Versus Patients Without Chronic Kidney Disease.

Authors:  David Clemons; Aaron Lee; Saaniya Ajmeri; Vittorio Terrigno; Jordan Zaid; Krystal Hunter; Satyajeet Roy
Journal:  J Clin Med Res       Date:  2021-06-25

Review 10.  Uremic Toxins and Their Relation with Oxidative Stress Induced in Patients with CKD.

Authors:  Anna Pieniazek; Joanna Bernasinska-Slomczewska; Lukasz Gwozdzinski
Journal:  Int J Mol Sci       Date:  2021-06-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.